Exicure Inc (XCUR)
NASDAQ:XCUR
Want to see XCUR full AI Analyst Report?
XCUR Stock Chart & Stats
$5.93
-$0.13(-1.36%)
At close: 4:00 PM EST
$5.93
-$0.13(-1.36%)
Day’s Range― - ―
52-Week Range$2.78 - $11.00
Previous CloseN/A
Volume39.94K
Average Volume (3M)23.77K
Market Cap
$18.10M
Enterprise Value$14.53M
Total Cash (Recent Filing)$3.75M
Total Debt (Recent Filing)$176.00K
Price to Earnings (P/E)―
Beta1.04
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding6,373,915
10 Day Avg. Volume33,737
30 Day Avg. Volume23,774
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)8.69
Price to Sales (P/S)0.00
P/FCF Ratio-3.99
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-92.56
Enterprise Value/Ebitda-1.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary SNA PlatformA proprietary SNA platform provides a durable technological moat: it enables multiple therapeutic programs across oncology and immunology, supports IP protection and partnerability, and allows the company to leverage platform improvements across candidates, sustaining long-term R&D optionality.
Debt Reduced To ZeroElimination of debt materially lowers financial risk and interest burden, improving flexibility to fund development or restructure financing without near-term insolvency pressure. A debt-free position strengthens runway options and makes future equity or partnership financings less encumbered.
Governance Reforms And New Operational LeadershipCourt-approved governance reforms plus appointment of a seasoned COO and new directors improve oversight and operational capability. Stronger controls and experienced management reduce execution and compliance risk, enabling clearer strategic focus and potentially faster, steadier program execution.
Bears Say
Heavy, Worsening Cash BurnPersistent and increasing negative operating cash flow signals the business is not self-funding. Continued cash burn forces reliance on external financing or asset sales, raising dilution risk and limiting the company's ability to invest predictably in trials or scale operations over the medium term.
Recurring Losses & Unstable RevenueChronic net losses and lumpy, non-recurring revenue reduce visibility and undermine margin sustainability. Without predictable revenue streams or near-term profitable products, the company remains dependent on milestone payments or financings, increasing execution and commercialization risk.
Thin, Shrinking Equity BaseA shrinking equity base limits the company's loss-absorbing capacity and reduces balance-sheet resilience to setbacks. Thin equity constrains borrowing capacity, increases the probability of dilutive capital raises, and leaves less buffer to fund development through clinical inflection points.
Exicure News
XCUR FAQ
What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $2.78 and its highest was $11.00 in the past 12 months.
What is Exicure Inc’s market cap?
Exicure Inc’s market cap is $18.10M.
When is Exicure Inc’s upcoming earnings report date?
Exicure Inc’s upcoming earnings report date is May 20, 2026 which is in 4 days.
How were Exicure Inc’s earnings last quarter?
Exicure Inc released its earnings results on Mar 25, 2026. The company reported -$0.455 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.455.
Is Exicure Inc overvalued?
According to Wall Street analysts Exicure Inc’s price is currently Overvalued.
Does Exicure Inc pay dividends?
Exicure Inc does not currently pay dividends.
What is Exicure Inc’s EPS estimate?
Exicure Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exicure Inc have?
Exicure Inc has 6,373,915 shares outstanding.
What happened to Exicure Inc’s price movement after its last earnings report?
Exicure Inc reported an EPS of -$0.455 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Exicure Inc?
Currently, no hedge funds are holding shares in XCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Exicure Inc
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Technical Analysis
Ownership Overview
25.09% Insiders
0.88% Mutual Funds
0.88% Other Institutional Investors
72.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---